OTC GLYCERIN/ALCOHOL COMBO FOR PREVENTION AND TREATMENT OF SWIMMER's EAR will be placed in Category III in the OTC Products monograph, OTC Div. Director Gilbertson told Commerce Drug in a recent "feedback" letter. Gilbertson said that data submitted by the firm was insufficient to support the indication for its Auro-Dri otic product, and added that the division "intends to recommend to the Commissioner that the agency classify 5% anhydrous glycerin in 95% isopropyl alcohol in Category III for "'the prevention of swimmer's ear and treatment of water-clogged ears.'" Noting that the claims of prevention of swimmer's ear and treatment of water-clogged ears were not considered by the OTC Otic Products Panel, Gilbertson said "that final monograph will deal only with earwax removal aids." However, the FDAer said the agency "will publish a separate proposed rule to amend the final monograph in a future Federal Register" in order to obtain public comment on whether the claims should be added to the monograph. Gilbertson told the company that the clinical data submitted indicated that the product "was successful in drying more than 50% of the water in the ears of 42 out of 49 patients within a five minute period." He noted, however, that "the data provided do not address the question of the effectiveness in preventing swimmer's ear, because the data did not show prevention or a reduction in the incidence of swimmer's ear in a susceptible target population." In addition, Gilbertson said that although the firm claims Auro-Dri is a combination product, "the data did not show the effectiveness of each ingredient alone." Stating that each ingredient must be tested alone and in combination if therapeutic claims are made for both ingredients, Gilbertson said "if glycerin functions only as an inactive ingredient, additional testing would not be required for this ingredient."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
